← Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-12-31 (est.)Phase 3 · Almonertinibimp 9/10
- 2027-03-01 (est.)Phase 2 · HS-20137imp 7/10
- 2027-03-07 (est.)Phase 3 · HS-20089imp 9/10
- 2027-05-30 (est.)Phase 2 · HS-10542imp 7/10
- 2027-07-10 (est.)Phase 2 · HS-10516 + Lenvatinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Adebrelimab Injection | Phase 2 | Non-Small Cell Lung Cancer |
| HS-20093 for Injection | Phase 2 | Non-Small Cell Lung Cancer |
| HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) |
| Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma |
| HS-20089 | Phase 2 | Ovarian Cancer |
| PEG-Tα1 | Phase 2 | Hepatitis B, Chronic |
| Aumolertinib | Phase 3 | Non-small Cell Lung Cancer |
| HS-10374 | Phase 2 | Psoriatic Arthritis |
| HS-10516 + Lenvatinib | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma |
| HS-10370 | Phase 2 | Advanced Solid Tumor |
| Flumatinib | Phase 3 | CML, CML-CP,MMR,TKI |
| HS-20117 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer |
| HS-10234 | Phase 3 | Chronic HBV Infection |
| HS-20094 injection | Phase 3 | Overweight |
| iloperidone | Phase 2 | Schizophrenia |
| Pegol-Sihematide | Phase 3 | Chronic Kidney Diseases |
| HS-10380 Low Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) |
| Almonertinib | Phase 3 | Lung Cancer |
| HS-20094 | Phase 2 | Overweight and Obesity |
| HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HNPHY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.